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Post-operative levamisole may compromise early healing of expérimental 
intestinal anastomoses
JW D de Waard*, T Wobbes, BM de Man, CJ van der Linden and T Hendriks
Department o f Surgery, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Summary There exists growing interest in immediate post-operative local adjuvant therapy after resection of 
intestinal malignancies. It is therefore necessary to assess its potential effect on the healing of intestinal 
anastomoses. Five groups (n = 20) of rats underwent resection and anastomosis of both ileum and colon: a 
control group and four experimental groups receiving intraperitoneal 5-fluorouracil (5-FU), 5-FU plus 
leucovorin, 5-FU plus levamisole or levamisole alone, on the day of surgery and the next 2 days. Animals were 
killed 3 or 7 days after operation. Another three groups (n = 6) of animals were used to compare anastomotic 
collagen synthetic capacity in control rats or rats receiving 5-FU or 5-FU plus levamisole. On the third 
post-operative day, the average anastomotic bursting pressure in the 5-FU/levamisole group was reduced by 
36% as compared with the control group, both in ileum {P — 0.02) and in colon (P =  0.01). Values in the 
other groups were similar to those in the control group. Anastomotic breaking strength was significantly 
(ƒ*< 0.025) lowered in the ileum from the levamisole group at both days 3 and 7. Anastomotic collagen 
synthetic capacity was strongly reduced in the 5-FU and 5-FU/levamisole groups. However, there was no 
significant difference between the control group and the four experimental groups with regard to anastomotic 
hydroxyproline concentration and content, either 3 or 7 days after operation. Thus, limited use of levamisole, 
alone or in combination with intraperitoneal 5-FU, may compromise intestinal healing.
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The recurrence rate is high after surgical treatment o f  col­
orectal cancer. This has prompted extensive clinical investiga­
tions into the use o f  chemotherapy as an adjunct to surgery. 
Until now, disappointing results have been obtained despite 
enormous preclinical and clinical research efforts. A lthough a 
meta-analysis o f  its use shows only limited benefit (Buyse et 
al., 1988), 5-Fluorouracil (5-FU) remains the m ost effective 
single agent, and current research aims to improve its efficacy 
by combinations with other agents (Mayer, 1992; Kemeny et 
al., 1993). A number o f  studies have confirmed an improved  
therapeutic activity if 5-FU is combined with folinic acid 
(leucovorin) (Mayer, 1992; Kemeny et al., 1993), while the 
combination o f  5-FU with levamisole also attracts con­
siderable attention (Moertel et a l 1990; Stevenson et al., 
1991). Major questions still to be resolved in the treatment o f  
patients by surgery and subsequent adjuvant chemotherapy  
include, next to the choice o f cytostatic agents, timing and 
route o f administration.
Recurrent disease is mainly found in the liver, at the 
operative site and on the peritoneal surface. It has been  
suggested that intraperitoneal chemotherapy would be better 
than systemic chemotherapy since it lowers the likelihood o f  
systemic complications while being efficient at the sites o f  
both local and distant -  hepatic -  recurrences (Cunliffe and 
Sugarbaker, 1989). Intraperitoneal 5-FU reportedly prevents 
hepatic metastasis in experimental colon cancer (Nordlinger 
et al., 1991). Since the efficiency of adjuvant therapy appears 
to be reduced with increasing time interval between operation  
and administration o f  cytostatic agents (Fisher et al., 1993), 
there are excellent reasons to start treatment immediately  
after operation (Harris and Mastrangelo, 1991) when the 
tumour burden is small. As a consequence, there exists grow ­
ing interest in immediate post-operative local adjuvant 
therapy after resection o f  intestinal malignancies (Sugarbaker 
et al., 1990; Sugarbaker, 1994). A number o f  studies using 
immediate post-operative intraperitoneal 5-FU are in pro­
gress (Glimelius and Pahlman, 1992; Graf et al., 1994).
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It thus becomes imperative to assess the potential effects o f  
such therapies on the healing o f  intestinal anastomoses. 
Administration o f  cytostatic agents in the perioperative 
period may be detrimental to anastomotic healing. Loss o f  
strength, particularly in the early phase when strength is 
relatively low, may increase the chances o f  anastomotic 
leakage, which is a potentially devastating surgical complica­
tion with concomitant high morbidity and mortality. Indeed, 
earlier experiments in our laboratory have shown that 
perioperative intraperitoneal combination chemotherapy con­
taining 5-FU, next to bleomycin and cisplatinum, greatly 
reduces anastomotic strength (de Roy van Zuidewijn et al., 
1991). Intraperitoneal 5-FU affects anastomotic collagen syn­
thetic capacity far more severely than intravenous 5-FU  
(Martens et al., 1992a). Daily intraperitoneal administration 
of 5-FU alone from the day o f  surgery onwards until 
sacrifice after 7 days strongly inhibits anastomotic repair in 
the rat intestine (Graf et al., 1992; de Waard et al., 1995). 
The present study was undertaken to assess if additional 
medication with leucovorin or levamisole would add to this 
negative effect. We reported recently that intraperitoneal 
administration o f  5-FU alone on the day o f  operation and 
the next 2 days does not significantly reduce strength in 
experimental intestinal anastomoses (de Waard et al., 1993). 
Since we expected any additional effect o f  leucovorin and 
levamisole to be more easily observed under conditions in 
which 5-FU alone does not (yet) impair anastomotic healing, 
we limited drug administration to the first 3 days.
Materials and methods
Animals
Altogether, 118 male outbred Wistar/Cpb:WU rats, weighing 
between 200 and 300 g, were used. They were housed two 
animals per cage and had free access to water and standard 
laboratory chow (diet AM  II, H ope Farms, Woerden, The 
Netherlands).
For the measurement o f  anastomotic strength and hydrox­
yproline content, 100 animals were randomly divided into 
five groups o f  20 animals each; a control group, a 5-FU  
group, a levamisole group and two groups receiving 5-FU  
plus levamisole or leucovorin. Within each group, ten rats
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were killed 3 and 7 days after operation. Collagen synthesis lected tissue explants of 1 -2  ram2, collected from control
was measured in three groups of animals (n =  6): a control segments removed at operation and from anastomotic tissue
group, a 5-FU group and a group which received 5-FU plus removed 3 days after operation, were incubated in medium 
levamisole. These rats were killed 3 days after operation.
The study was approved by the Animal Ethics Review
containing ['Hjproline for 3 h and the radioactivity incor­
porated into total protein was counted. Subsequently, in
Committee of the Faculty of Medicine, University of order to determine proline incorporation into collagen, excess 
« t  • _  . ^Nijmegen. purified collagenase was The radioactivity in the
Drug administration
5-FU (Abie, Netanya, Israel) was given intraperitoneally in a 
dose of 20 mg kg-1 body weight (concentration lm gm l-1 
saline). This is the same dose we used previously (de Waard
supernatant represents CDP, as a measure of the amount of 
collagen synthesised. Subtraction of the radioactivity in the 
CDP fraction from that in total protein yields the incorpora-
. The relative coi­tion into non-collagenous protein
lagen synthesis (RCS) was calculated with the formula (Peter- 
kofsky et a/., 1981) that takes into account the enrichment of
et al . ,  1993, 1995) and represents the highest dose which, in proline in collagen compared with other proteins:
combination with surgery, did not in a significant
mortality. Levamisole (Janssen, Beerse, Belgium) was given 
orally, by means of a stomach tube, in a dosage of 5 mg kg"1 
body weight. Leucovorin (Cyanamid, Etten-Leur, The 
Netherlands) was administered intravenously in a dosage of 
10 mg kg-1 body weight. All drugs were given once a day, on 
the day of operation and the next 2 days. The animals in the 
control groups received intraperitoneal saline daily.
Relative collagen 
synthesis (%)
V i w j *  I I . . . .  '  •* " i f  r  ■ ¿  r  • . . 4 . I I |  I  ;■
(NCP X 5.4) + CDP
X 100%
Incorporation is expressed on the basis of sample wet weight, 
DNA (Burton, 1956) content or protein (Smith et al . ,  1985) 
content.
0 perative procedure
After an intraperitoneal injection of sodium pentobarbital, a 
midline incision was made and 1 cm of both small and large 
bowel was resected at 15 cm proximal to the ileocaecal junc­
tion and 3 cm proximal to the rectal peritoneal reflection 
respectively. Continuity was restored microsurgically by the 
construction of an inverted one-layer seromuscular end-to- 
end anastomosis with eight interrupted sutures of 8 x 0  
monofilament material (Ethicon, Sommerville, USA). The 
abdomen was closed in two layers with a continuous 3 x 0  
silk suture for the fascia and staples for the skin.
St at istical anal vs is
Pairwise comparisons of groups were performed with a Wil- 
coxon test using a level of significance of 2a/k, where k is the 
total number of pairwise comparisons.
This way, comparison of the four experimental groups 
with the control group (Figures 1-3) yields a significant 
difference if /)<0.025. Comparison of the two experimental 
groups which were used to analyse collagen synthesis with 
the control group (Figure 1 and Tables I and II) yields a 
significant difference at P < 0.05.
Results
A nalytical procedures
The rats were killed by an intraperitoneal overdose of sodium 
pentobarbital. After opening the abdominal wound and iden­
tifying the anastomoses, the adhesions were cut as far as 
possible without injuring the intestine. An intestinal segment 106% of weight before operation. Rats in all four experi- 
with the anastomosis in the middle was removed, with the mental groups exhibited qualitatively and quantitatively 
sutures left in place. This
No animals died prematurely. All rats lost weight after oper­
ation. In the control group the average maximal weight loss 
was 9% on the first post-operative day. Thereafter, animals
day 7, the average body weight was
was attached to an
infusion pump filled with methylene blue-stained saline. The 
pressure was raised with an infusion rate of 4m lm in"1 and
Both the
maximum pressure 
of pressure, and the site of rupture were noted.
similar changes in 
The average anastomotic bursting pressure - a measure of 
resistance to increasing intraluminal pressure - at day 3 is 
depicted in Figure 1. At this time point, the bursting site was 
always within the suture line. 5-FIJ, administered either alone 
or in combination with leucovorin, did not significantly lower
the segment was placed in a tensiometer and the breaking the bursting pressure. However, if levamisole and 5-FU were
4  A r t  «  t a  A  A  m  m  m  +* A  *  mstrength was recorded. Thus, the bursting pressure and given simultaneously, the anastomotic t \  L<
breaking strength were measured in the same anastomotic significantly reduced by 36%, both in the ileum (/' = 0.02) 
segment. The validity of this procedure had been confirmed and in the colon (ƒ> = 0,01). Levamisole alone had no effect.
in a pilot Two of 20 animals were
operated and killed after 3 or 7 days (n — 10 each). In the
first group, only the anastomotic breaking 
measured: in the ileum, average values were 23 ± 7 (s.d.) g at 
day 3 and 128 ± 35 g at day 7. In the second group, measure­
ment of the bursting pressure preceded analysis of the break­
ing strength. Still, the breaking strength in this group 
similar levels, 19 ± 12 g and 127 ± 33 g respectively, 
wise, similar values for the colonic breaking strength were 
found in both groups.
The anastomotic segment was then cleaned from 
rounding tissue and a 5 mm segment with the suture
O)c  cn
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n  Eo
150
<u
s u r
in
the middle was collected. The samples were frozen immed­
iately and stored in liquid nitrogen until processing, 
weighing, the samples were pulverised and lyophilised and 
the hydroxyproline content was measured as described 
previously (Hesp et al., 1984).
Collagen synthesis was analysed as the ex vivo 
synthetic capacity in intestinal explants by measuring the 
incorporation of proline into collagenase-digestible protein 
(CDP), according to a procedure validated before for rat 
intestinal tissue (Martens et al., 1992b). Briefly, freshly col-
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Figure I Anastomotic bursting pressure after 3 days. Bars repre-
10, except for control group, where
2, 5 -F U  group; 3, 5-FU/
sent average values (»
Contro ln 8) + s.d. 1,
leucovorin group; 4, 5-1* 
■“Significantly (/><0.025, 
from control group.
group;
amisole group; 5, levamisole group, 
see Materials and methods) different
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Figure 2 Anastomotic breaking strength. Bars represent average 
values (n = 10) +  s.d. 1, Control group; 2, 5-FU group; 3, 5-FU/ 
leucovorin group; 4, 5-FU/levamisole group; 5, levamisole group. 
"■Significantly (J°<0.025, see Materials and methods) and 
+ almost-significantly (P<0.05) different from control group.
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Figure 3 Anastomotic hydroxyproline content. Bars represent 
average values {n =  10) +  s.d. 1, Control group; 2, 5-FU group; 3, 
5-FU/leucovorin group; 4, 5-FU/levamisole group; 5, levamisole 
group.
Table I Ex vivo synthesis of collagen and non-collagen protein in ileal anastomoses
Control group 5-FU group 5-FU ¡LEV group
Collagen
d. p. m./total 36 926 ±  7784 15 053 ±  4092* 17 325 ±  5225*
d.p.m. jug- 1 DNA 194 ±  30 115 ±30* 126 ±  33*
d.p.m. mg” 1 wet weight 595 ±  72 297 ±  47* 310 ±  41*
d.p.m. mg“ 1 protein 14 786 ±  1953 6819 ±  1292* 8573 ±  1912*
RCS (%) 1.02 ±0.18 0.73 ±0.10* 0.60 ±  0.06*
Non-collagen
d.p.m./total 626 155 ± 81 428 384 147 ±  96 986* 522 343 ±  17 2077
d.p.m. ng~' DNA 3015 ± 770 2912 ±  716 3747 ±  1045
d.p.m. m g '1 wet weight 9697 ±  1572 7556 ±  1215 9439 ±  1355
d.p.m. mg“ 1 protein 246 721 ±  81 428 180 250 ± 2 7  049 255 754 ±  48 956
Explants from anaslomotic tissue were collected 3 days after operation and incubated for 3 h with
4.5 fxCi of['H]proline. Collagen synthesis is expressed as radioactivity in collagenase-digestible protein and 
as percentage relative collagen synthesis (RCS). Non-collagen protein synthesis is expressed as 
radioactivity in non-collagenous protein. Data represent average values ( +  s.d) from six animals. 
■"Significant (/,<0.05) difference with the control group.
Table II Ex vivo synthesis of collagen and non-collagen protein in colonic anastomoses
Collagen 
d.p.m./total 
d.p.m./fig*1 D N A  
d.p.m. mg'"1 wel weight 
d.p.m. m g “ 1 protein
RCS {%)
Control group
57 467 ± 20 399 
221 ± 62 
773 ± 150 
17 454 ± 3214
1.72 ± 0.32
5-FU group
r r t
31 723 ±  11491* 
132 ±  26*
429 ± 80* 
9490 ± 1997* 
1.29 ±  0.19*
5-FU I LEV group
21 269 ± 7375* 
101 ± 22* 
337 ± 58* 
6948 ± 2611 * 
1.04 ± 0 . 17*
Non-collagen 
d.p.m./total 
d.p.m. 1 D N A  
d.p.m. mg 1 wet weight 
d.p.m. mg 1 protein
**«
670 878 ± 62 818 
2423 ± 794 
9168 ± 1597 
198 06H ± 4 1 505
438 772 ± 120 923* 
1902 ± 239 
6175 ± 723*
135 985 ± 16 191*
488 899 ± 64 8 17* 
1836 ± 383 
6267 ± 673*
127 056 ± 34 833*
Explains from anastomotic tissue were collected 3 days after operation and incubated for 3 h with
4.5 jtiCi of [’HJproline. Collagen synthesis is expressed as radioactivity in collagenase-digestible protein and 
as percentage relative collagen synthesis (RC\S). Non-collagen protein synthesis is expressed as 
radioactivity in non-collagenous protein. Data represent average values ( 4* s.d.) from six animals. 
^Significant (^ <0.05) difference with the control group.
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Figure 4 Collagen synthetic capacity in control and anastomotic 
segments. Bars represent average values (n = 6) 4- s.d. Ex vivo 
collagen synthesis in control segments removed at operation 
(closed bars) and in anastomotic tissue collected 3 days after 
operation (open bars). *Signilicantly ( /><0.05) different from 
control group.
At 7 days after operation the bursting site was always outside 
the suture line. Therefore, the bursting pressures measured at 
this time (data not shown) did not represent actual anas­
tomotic strength.
The average anastomotic breaking strength, a measure of 
the ability to withstand longitudinal forces, is shown in 
Figure 2. The breaking site was invariably within the wound 
area both 3 and 7 days after operation. At day 3, similar 
values were found in the control, 5-FU and 5-FU/leucovorin 
groups. The average breaking strength in both the 5-FU/ 
levamisole and the levamisole group was lower than in the 
control group. However, this effect was only
= 0.016) in ileal anastomoses in the levamisole group. At 
day 7, ileal anastomoses in the 5-FU/leucovorin (P — 0,018) 
and levamisole (P =  0.025) groups were significantly weaker 
than those in the control group. This was almost {P = 0. 
the case for colonic anastomoses in the 5-FU/levamisole 
group.
Hydroxyproline, as a measure of collagen, was quantitated 
in 5 mm segments containing the anastomosis (Figure 3). No 
differences between the control group and the various experi­
mental groups were observed. In the control group the hyd­
roxyproline content increased from day 3 to day 7 by a 
factor of 2.7 in ileal anastomoses and by a factor of 1.6 in 
colonic anastomoses. This increase was similar in the animals 
receiving the various cytostatic drugs. Likewise, no differ­
ences were found for the hydroxyproline concentrations in 
the anastomotic segments. Average hydroxyproline concent­
rations were 7.0 ± 1.3 and 9.6 ± 1.8 fig mg”1 dry weight in 3- 
and 7-day-old ileal anastomoses respectively; corresponding 
values in colonic anastomoses were 9.7 ± 0.7 and 13.8 ± 
1.9 jig mg-1 dry weight. Similar values were measured in the 
experimental groups (data not shown).
We also compared the collagen synthetic capacity, meas­
ured ex vivo in tissue explants, in the control, 5-FU and 
5-FU/levamisole groups 3 days after operation. In the cont­
rol group, this was strongly increased in anastomotic tissue in 
comparison with control segments removed at operation 
(Figure 4), 5-fold in ileum and nearly 3-fold in colon. In both 
experimental groups anastomotic collagen synthetic capacity,
calculated on the basis of DNA content, was significantly 
reduced. This effect was also evident if collagen synthesis was 
expressed per anastomosis (d.p.m./total) or on the basis of 
wet weight or protein (Tables I and II). Synthesis of non- 
collagenous proteins was affected less strongly, particularly in 
the ileum. We found no differences between the 5-FU and 
the 5-FU/levamisole groups.
Discussion
If resection of an intestinal tumour is followed immediately
by adjuvant this procedure constitutes a
potential hazard for the healing anastomosis. The present 
results confirm that 5-FU alone, administered on the day of
the next 2 days, does not ísurgery ;
the development of anastomotic strength in the first post­
operative week. However, levamisole indeed appears to exert 
a negative eflfect in this respect. The strength of the intact 
and anastomosed intestinal wall is largely derived from col­
lagen, the major structural protein in the submucosal layer.
isDuring the post-operative days wound
thought to solely depend on the suture-holding capacity of 
existing collagen fibrils (Hogstrom et al., 1985). From app­
roximately 3 days after operation, the anastomosis starts to 
gain strength. Restoration of strength to the level of the 
uninjured intestine depends on de novo synthesis of collagen. 
In the control animals, the anastomotic collagen synthetic 
capacity is already strongly stimulated after 3 days and the 
anastomotic collagen (hydroxyproline) content increases con­
siderably between 3 and 7 days after operation; a similar rise 
in breaking strength is observed over the same period. 
Administration of 5-FU until day 3 significantly reduces the 
collagen synthetic capacity in the anastomotic area without 
affecting anastomotic strength measured 3 or 7 days after 
operation. This indicates that the enhanced collagen synthetic 
capacity, which may be observed as early as 3 h after oper­
ation (Martens and Hendriks, 1991) is not necessary -  at
-  for retaining wound strength during the 
first post-operative days. The fact that the increase between 3 
and 7 days in both anastomotic strength and collagen con­
tent is unimpeded in the 5-FU group means that the collagen 
synthetic capacity is normalised very quickly after cessation 
of drug administration. Alternatively, it could be argued that
not
the collagen capacity normally in the
is
wound area in fact constitutes an overcapacity: it is not fully 
used for collagen deposition and a moderate inhibition does 
not necessarily lead to diminished accumulation of wound 
collagen. Thus, immediate post-operative chemotherapy with 
5-FU alone, administered for 3 days, appears to be relatively 
harmless for anastomotic integrity. However, if the drug is 
given over a
(Graf et a/., 1992; de Waard et al.,
It seems well established that the therapeutic activity of 
5-FU can be improved by biochemical modulation with 
leucovorin (folinic acid) (Mayer, 1992; Kemeny et al., 1993). 
Graf et al. (1992) recently reported on the effect of simul­
taneous administration of 5-FU and leucovorin on anas­
tomotic healing in the rat colon. In this experiment, the 
drugs were given daily until sacrifice at day 7, This way, 
5-FU alone reduced anastomotic strength and addition of 
leucovorin does not lead to further deterioration. The present 
experiment where 5-FU administration is limited to the first 3 
days and does not by itself reduce anastomotic strength, does 
not fully support these results. Although neither the bursting 
pressure nor the breaking strength of the anastomoses is 
affected by day 3, the ileal breaking strength is reduced 
significantly in the 5-FU/leucovorin group 7 days after oper­
ation. This finding precludes the unequivocal conclusion that 
addition of leucovorin to a post-operative regimen of 5-FU 
constitutes no additional hazard for anastomotic healing in 
the intestine and warrants further investigation.
Post-operative chemotherapy with 5-FU and 
may also be beneficial to a certain class of patients with 
colorectal carcinoma (Moertel el al., 1990; Stevenson et al,
Levamisole and anastomotic healing
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1991). Levamisole, in conjunction with intravenous 5-FU, 
has already been given in a small study on the first 3 post­
operative days following curative surgery for colorectal 
cancer (Windle et al., 1987). Our results indicate that 
levamisole, administered immediately after operation alone 
or in combination with intraperitoneal 5-FU, may be harm­
ful to the development of anastomotic strength. In particular, 
the bursting pressure of 3-day-old anastomoses is reduced in 
the 5-FU/levamisole group but not in the 5-FU group. Also, 
the average anastomotic breaking strength in the levamisole 
group is reduced after both 3 and 7 days, though significantly
so only in the ileum.
Comparison of the collagen synthetic capacity in 3-day-old
collagen content is similar in all groups, the methodology 
used would be unable to detect very localised loss ot collagen 
restricted to, for instance, the immediate area around the 
sutures (Hendriks and Mastboom, 1990). it may be that 
levamisole somehow stimulates collagenolysis. Levami.1 
has been reported to exert a broad range oi immun­
omodulatory effects (Stevenson et al., 1991). It increases the 
chemotactic response of granulocytes, which cells accumulate 
immediately after wounding in the anastomotic area and are 
an important source for collagenolytic enzymes (Hasty et a/., 
1990). Also, levamisole up-regulates interleukin 1 (IL-1.) pro­
duction by macrophages (Kimball et a l 1992), and IL-1 is 
known to strongly enhance collagenase production by iibro-
anastomoses yields no difference between the 5-FU and 5- blasts and other cells (Circolo et aL  1991)
*  _ ~ ^  ^  1 > i  i  1 .. J. 1 ___^ ^ A i  4*. « '■« f i  ji-'v
We
at this time point anastomotic strength is probably indepen­
dent of de novo collagen synthesis and largely depends on
‘old’ collagen. Degradation of existing collagen fibrils, which ------ - _ . . .
provide strength to the matrix anchoring the sutures, may negatively affect intestinal healing. The mechamsm(s) rexpon-
result in loss of wound strength. Although the anastomotic sible for this effect remain to be elucidated.
Thus, our data suggest that limited use of 5-FU, in com­
bination with leucovorin, may not be entirely harmless to 
anastomotic repair. Administration of levamisole, alone or in 
combination with 5-FU, in the perioperative
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